Chongqing Lummy Pharmaceutical (300006) — Tangible Net Worth Ratio
Chongqing Lummy Pharmaceutical (300006) has a Tangible Net Worth Ratio of 87.6% as of September 2025. This metric is calculated by deducting intangible assets (CN¥230.06 Million) from net assets (CN¥1.85 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore 300006 net assets growth trend to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Chongqing Lummy Pharmaceutical Tangible Net Worth Ratio (2006–2024)
This chart shows how Chongqing Lummy Pharmaceutical's Tangible Net Worth Ratio has changed across 19 annual periods from 2006 to 2024. As of September 2025, the ratio stands at 87.6%, reflecting net assets of CN¥1.85 Billion with intangible assets of CN¥230.06 Million CNY. For live market cap and overall valuation, see 300006 market cap.
Annual Tangible Net Worth Ratio for Chongqing Lummy Pharmaceutical (2006–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Chongqing Lummy Pharmaceutical from 2006 to 2024, covering 19 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore Chongqing Lummy Pharmaceutical capital spending ratio to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 88.5% | CN¥1.88 Billion | CN¥217.27 Million | CN¥2.86 Billion | ▼ -1.5 pp |
| 2023 | 90.0% | CN¥2.12 Billion | CN¥212.00 Million | CN¥2.89 Billion | ▲ +1.0 pp |
| 2022 | 89.0% | CN¥2.18 Billion | CN¥240.15 Million | CN¥3.05 Billion | ▼ -3.1 pp |
| 2021 | 92.1% | CN¥2.21 Billion | CN¥174.85 Million | CN¥2.93 Billion | ▲ +11.0 pp |
| 2020 | 81.1% | CN¥1.23 Billion | CN¥233.36 Million | CN¥3.15 Billion | ▲ +0.4 pp |
| 2019 | 80.7% | CN¥1.65 Billion | CN¥319.35 Million | CN¥3.50 Billion | ▲ +3.1 pp |
| 2018 | 77.6% | CN¥1.72 Billion | CN¥386.48 Million | CN¥3.14 Billion | ▼ -1.4 pp |
| 2017 | 79.0% | CN¥1.72 Billion | CN¥362.26 Million | CN¥2.74 Billion | ▲ +0.2 pp |
| 2016 | 78.7% | CN¥1.67 Billion | CN¥355.88 Million | CN¥2.48 Billion | ▼ -1.4 pp |
| 2015 | 80.2% | CN¥1.69 Billion | CN¥335.35 Million | CN¥3.10 Billion | ▲ +10.4 pp |
| 2014 | 69.8% | CN¥1.02 Billion | CN¥307.58 Million | CN¥2.24 Billion | ▼ -6.0 pp |
| 2013 | 75.7% | CN¥1.13 Billion | CN¥273.23 Million | CN¥2.18 Billion | ▲ +1.5 pp |
| 2012 | 74.3% | CN¥710.51 Million | CN¥182.84 Million | CN¥1.42 Billion | ▼ -2.8 pp |
| 2011 | 77.1% | CN¥660.17 Million | CN¥151.12 Million | CN¥1.08 Billion | ▼ -7.6 pp |
| 2010 | 84.7% | CN¥561.59 Million | CN¥86.08 Million | CN¥884.01 Million | ▼ -10.7 pp |
| 2009 | 95.4% | CN¥525.08 Million | CN¥24.41 Million | CN¥653.63 Million | ▲ +12.0 pp |
| 2008 | 83.4% | CN¥137.79 Million | CN¥22.93 Million | CN¥268.56 Million | ▼ -2.7 pp |
| 2007 | 86.1% | CN¥107.91 Million | CN¥15.02 Million | CN¥214.69 Million | ▲ +2.6 pp |
| 2006 | 83.5% | CN¥64.39 Million | CN¥10.64 Million | CN¥125.10 Million | — |